For the past two years, the Minnesota House committee that oversees bioscience development held a special hearing on why Minnesota needs an angel investor tax credit to boost high tech companies. And for the past two years, nothing happened.

The biotech startup VitalMedix, which is developing a drug to protect bodies from severe blood loss, is leaving to take advantage of a Wisconsin tax-credit program. Other companies may follow.

The company makes Tamiasyn, which in animal tests protected cells, organs and tissue after more than 60-percent blood loss.